T. Rowe Price Associates
IMMX icon

T. Rowe Price Associates’s Immix Biopharma IMMX Stock Holding History

T. Rowe Price Associates’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9M Buy
1,739,919
+1,324,918
+319% +$12.3M ﹤0.01% 1180
2026
Q1 		$3.78M Buy
+415,001
New +$3.05M ﹤0.01% 1544

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

T. Rowe Price Associates's IMMX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Immix Biopharma (IMMX) stake by 319% in Q2 2026, buying an estimated $12.3M and bringing the position to 1,739,919 shares worth $17.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1180.

T. Rowe Price Associates first reported a position in IMMX in Q1 2026 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • T. Rowe Price Associates held 1,739,919 shares of Immix Biopharma worth $17.9M as of Q2 2026.
  • T. Rowe Price Associates bought 1,324,918 Immix Biopharma shares in Q2 2026, an estimated $12.3M.
  • Immix Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1180 holding.
  • T. Rowe Price Associates first reported a position in Immix Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.